<DOC>
	<DOC>NCT00120393</DOC>
	<brief_summary>Patients with HIV who are virologically suppressed on a lopinavir/ritonavir combination highly active antiretroviral therapy (HAART) regimen but with elevated non-HDL cholesterol are randomized to remain on lopinavir/ritonavir or change to atazanavir/ritonavir in combination with current nucleoside reverse transcriptase inhibitors (NRTIs).</brief_summary>
	<brief_title>Study of HIV Patients With Undetectable Viral Load and Abnormal Lipids Switching to Atazanavir/Ritonavir</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Atazanavir Sulfate</mesh_term>
	<criteria>HIV positive LPV/RTVbased HAART for at least 6 months HIV1 RNA less than 50c/mL (confirmed) NonHDL higher than 160 mg/dL CD4 of at least 50 cells/mL Use of lipidlowering agents</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2009</verification_date>
	<keyword>Treatment Experienced</keyword>
</DOC>